I take care of patients both in the hospital and in the clinic, and consult with nearly all of our disease management teams on patients with a diversity of cancers. I led a team that developed an algorithm for insulin use in inpatients that is now a Memorial Sloan-Kettering standard. Some experimental chemotherapeutic agents can cause or worsen diabetes, and I have been a co-investigator on several clinical trials of new cancer drug alternatives. I have been an invited guest at many grand rounds lectures to speak about blood-sugar control and its importance in cancer management.
I am also involved in training medical interns in Memorial Sloan-Kettering’s Transitional Year Residency Program, and in guiding endocrinology fellows in the joint program between our hospital and Weill Cornell Medical College.
On a national level, I am an active member of the American Diabetes Association and the American Association of Clinical Endocrinologists, and I sit on the board of directors for both the American Journal of Hypertension and the Metropolitan Diabetes Society.